ArticleFrontiers in oncology2025
Surgical treatment of giant phyllodes tumors of the breast: a series of rare cases.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Phyllodes tumors (PTs) are rare interstitial tumors that account for <1% of all breast tumors. The best surgical option for PTs is controversial, particularly in patients with giant PTs. Methods: This retrospective single-center study selected patients with giant borderline/malignant PT (>10 cm) treated in our center between January 2017 and July 2022. We conducted a detailed analysis and identified rare cases. Survival analysis was performed using the Kaplan-Meier method. Results: This study included 24 patients with PTs >10 cm, including 15 borderline and nine malignant PTs. Among these patients, 12 underwent extended lumpectomy and 12 underwent mastectomy at initial diagnosis. All patients were followed up for a median of 49.8 months. Local recurrence occurred in 50% of the patients who underwent lumpectomy, whereas none of the patients who underwent mastectomy and achieved R0 resection had recurrence. Several special cases are described in detail separately. Conclusion: Mastectomy may reduce local recurrence rates in patients with giant borderline/malignant PTs of the breast. Complete tumor resection and clean margins are the most important factors in controlling local recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.